Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $63.70, for a total value of $191,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Clovis Oncology, Inc. (NASDAQ CLVS) traded down $3.67 during trading on Friday, reaching $63.21. The company had a trading volume of 1,440,000 shares, compared to its average volume of 1,230,000. Clovis Oncology, Inc. has a 1 year low of $33.23 and a 1 year high of $99.45. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.06). The company had revenue of $16.81 million for the quarter, compared to analysts’ expectations of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same quarter in the prior year, the business posted ($1.70) EPS. sell-side analysts forecast that Clovis Oncology, Inc. will post -7.31 earnings per share for the current year.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/clovis-oncology-inc-clvs-insider-gillian-c-ivers-read-sells-3000-shares/1712314.html.

A number of research firms have commented on CLVS. Zacks Investment Research raised Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a report on Tuesday, October 17th. Leerink Swann reissued an “outperform” rating and issued a $90.00 target price (down previously from $107.00) on shares of Clovis Oncology in a report on Wednesday. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Clovis Oncology in a report on Monday, September 11th. Barclays PLC began coverage on Clovis Oncology in a report on Monday, October 23rd. They issued an “overweight” rating and a $105.00 target price for the company. Finally, BidaskClub downgraded Clovis Oncology from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 9th. Eight research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Clovis Oncology currently has a consensus rating of “Buy” and an average target price of $86.15.

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Clovis Oncology by 10.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,618,843 shares of the biopharmaceutical company’s stock worth $338,831,000 after purchasing an additional 333,648 shares in the last quarter. Orbimed Advisors LLC grew its holdings in Clovis Oncology by 13.5% in the 3rd quarter. Orbimed Advisors LLC now owns 2,388,670 shares of the biopharmaceutical company’s stock valued at $196,826,000 after buying an additional 284,300 shares during the period. State Street Corp grew its holdings in Clovis Oncology by 4.3% in the 2nd quarter. State Street Corp now owns 1,943,480 shares of the biopharmaceutical company’s stock valued at $181,966,000 after buying an additional 80,171 shares during the period. Franklin Resources Inc. grew its holdings in Clovis Oncology by 70.3% in the 2nd quarter. Franklin Resources Inc. now owns 1,665,200 shares of the biopharmaceutical company’s stock valued at $155,913,000 after buying an additional 687,300 shares during the period. Finally, Jennison Associates LLC grew its holdings in Clovis Oncology by 222.5% in the 2nd quarter. Jennison Associates LLC now owns 1,185,177 shares of the biopharmaceutical company’s stock valued at $110,968,000 after buying an additional 817,677 shares during the period. Hedge funds and other institutional investors own 98.53% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.